For patients with relapsing-remitting multiple sclerosis (MS), rituximab is not noninferior to ocrelizumab, according to a study published online June 12 in JAMA Neurology. Izanne Roos, M.B.Ch.B., ...
Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...
The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection for people with relapsing ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
For multiple sclerosis, the therapy will be sold as Kesimpta by Novartis; it is administered by patients once a month through the Sensoready autoinjector pen. The FDA on Thursday approved a new ...
Rituximab is noninferior to ocrelizumab for suppressing disease activity among people newly diagnosed with relapsing multiple sclerosis.
The appraisal committee considered evidence submitted by Novartis, and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...
The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of teriflunomide, having considered evidence on the nature of active relapsing–remitting multiple sclerosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results